Actualités bioAffinity Technologies Inc - BIAF | Actions NASDAQ

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...

bioAffinity Technologies Set for Continued Expansion in 2025

Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a...

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of...

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex...

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement PR...

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement PR...

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

bioAffinity Technologies Inc (BIAF)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

BIAF Actualités

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies Set for Continued Expansion in 2025

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

bioAffinity Technologies Inc (BIAF) Actualités

bioAffinity Technologies Inc (BIAF)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

BIAF Actualités

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies Set for Continued Expansion in 2025

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application